BBO-11818 in Adult Subjects With KRAS Mutant Cancer

NCT06917079 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

387

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer
NSCLC
PDAC - Pancreatic Ductal Adenocarcinoma
CRC (Colorectal Cancer)
Metastatic Non-Small Lung Cell Cancer
Metastatic Colorectal Cancer (CRC)
KRAS G12A
KRAS G12C
KRAS G12D
KRAS G12S
KRAS G12V
Metastatic Pancreatic Ductal Adenocarcinoma
Advanced Lung Carcinoma
Solid Tumor, Adult

Interventions

DRUG: BBO-11818
DRUG: Pembrolizumab
DRUG: Platinum chemotherapy (cisplatin or carboplatin)
DRUG: Pemetrexed
DRUG: Cetuximab
DRUG: FOLFOX
DRUG: NALIRIFOX
DRUG: Gemcitabine
DRUG: Nab-paclitaxel

Sponsor

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)